Pregabalin Capsule
Product Images NDC 70518-4715

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-4715). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Label for Pregabalin Capsule C-V 75 mg oral capsules, packaged in a quantity of 30. The label states the product NDC as 70518-4715-00. It includes safety cautions about federal law prohibiting transfer and storage instructions, and notes repackaging by RemedyRepack Inc., Indiana, PA. The capsules are described as orange and white.*

FDA Label Image

Pregabalinfigure1 (Pregabalinfigure1)

A line graph depicting percent improvement in pain from baseline versus percent of patients improved. It compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo. The graph shows a trend of decreasing patient improvement percentages as pain improvement thresholds increase.*

FDA Label Image

Pregabalinfigure10 (Pregabalinfigure10)

A line graph comparing the estimated percentage of subjects without LTR over a period of 180 days for Pregabalin versus placebo. The x-axis represents days, and the y-axis shows the estimated percentage of subjects without LTR. Two lines are plotted: a solid line for Pregabalin and a dashed line for placebo.*

FDA Label Image

Pregabalinfigure11 (Pregabalinfigure11)

A line graph showing the percent of subjects improved over time from baseline to Week 12 measured by BOCF, comparing Pregabalin and Placebo. The x-axis represents percent improved, and the y-axis shows the percent of subjects improved. Pregabalin shows a higher percentage of improvement compared to Placebo throughout the observed range.*

FDA Label Image

Pregabalinfigure12 (Pregabalinfigure12)

A line graph comparing the percent of subjects improved from baseline to Week 16 BOCF between Pregabalin and placebo groups. The x-axis shows percent improved from 0 to 100%, and the y-axis shows percent of subjects improved from 0 to 100%. The Pregabalin group shows a higher rate of improvement than the placebo group across the range.*

FDA Label Image

Pregabalinfigure2 (Pregabalinfigure2)

A line graph showing the percent of patients improved plotted against the percent improvement in pain from baseline. The graph compares two treatments: Pregabalin 100 mg three times a day and placebo, with the Pregabalin line showing a higher percentage of improved patients across different pain improvement ranges.*

FDA Label Image

Pregabalinfigure3 (Pregabalinfigure3)

A line graph showing percent of patients improved plotted against percent improvement in pain from baseline. The graph compares Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken two times a day, as well as a placebo group, showing varying levels of patient improvement corresponding to pain reduction percentages.*

FDA Label Image

Pregabalinfigure4 (Pregabalinfigure4)

A line graph comparing the percent of patients improved against the percent improvement in pain from baseline for Pregabalin dosed at 200 mg and 100 mg three times a day versus placebo. The graph shows the trend of patient improvement over a range of pain improvement percentages.*

FDA Label Image

Pregabalinfigure5 (Pregabalinfigure5)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph shows trends of pain improvement across different dosage groups and placebo over the improvement percentage range.*

FDA Label Image

Pregabalinfigure6 (Pregabalinfigure6)

A bar chart comparing responder rates (%) by dosage in two studies (E1 and E3) for Pregabalin. Study E1 shows increasing responder rates for doses from placebo to 600 mg/day BID, while Study E3 compares placebo and doses at 600 mg/day taken either BID or TID, with higher responder rates at treatment doses than placebo. Data includes sample sizes (N) below bars.*

FDA Label Image

Pregabalinfigure7 (Pregabalinfigure7)

A line graph showing seizure reduction as median percentage change from baseline across different doses of pregabalin (mg/day). The graph compares four different studies (E1 BID, E2 TID, E3 BID, E3 TID) with markers and p-values indicating significant seizure reduction compared to placebo.*

FDA Label Image

Pregabalinfigure8 (Pregabalinfigure8)

A bar chart showing responder rates (%) for Pregabalin at doses of 2.5 mg/kg/day and 10 mg/kg/day compared to placebo. The chart includes values for placebo (22.6%, n=93), 2.5 mg/kg/day (29.1%, n=103), and 10 mg/kg/day (40.6%, n=96), illustrating increased responder rates with higher doses of Pregabalin.*

FDA Label Image

Pregabalinfigure9 (Pregabalinfigure9)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin daily doses of 600 mg, 450 mg, 300 mg, and placebo. The graph compares efficacy across different dosages and placebo over a range of pain improvement percentages.*

FDA Label Image

Pregabalinstructure (Pregabalinstructure)

Chemical structure of Pregabalin, showing the molecular arrangement with amino (NH2), methyl (CH3), and carboxyl (COOH) groups in a capsule dosage form context.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.